Cellectar Biosciences (CLRB) Retained Earnings (2010 - 2026)
Cellectar Biosciences (CLRB) posted Retained Earnings of -$269.1 million for Q4 2025, down 2.01% sequentially from -$263.8 million in Q3 2025, and down 203.07% YoY from $261.1 million in Q4 2024.
Cellectar Biosciences (CLRB) Retained Earnings (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Retained Earnings for 16 years, with the latest figure at -$269.1 million in Q4 2025.
- Quarterly Retained Earnings fell 203.07% year-over-year to -$269.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$269.1 million (down 203.07% YoY) and the FY2025 annual result came in at -$269.1 million, down 203.07% from the prior year.
- Retained Earnings retreated to -$269.1 million in Q4 2025 per CLRB's latest filing, from -$263.8 million in the prior quarter.
- Over five years, Retained Earnings peaked at $265.0 million in Q2 2025 and troughed at -$269.1 million in Q4 2025.
- A 5-year average of $5.6 million and a median of $66.1 million in 2021 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings soared 764.6% in 2022, then sank 236.31% in 2024.
- Over 5 years, Retained Earnings stood at -$25.3 million in 2021, then jumped by 764.6% to $168.1 million in 2022, then rose by 8.79% to $182.9 million in 2023, then surged by 42.75% to $261.1 million in 2024, then tumbled by 203.07% to -$269.1 million in 2025.
- According to Business Quant data, Retained Earnings over the past three periods registered -$269.1 million, -$263.8 million, and $265.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.00 Bn | 132.14 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.24 Bn | 60.06 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 62.41 Bn | 57.27 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.18 Bn | 27.88 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.93 Bn | 10.54 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.44 Bn | - | 4.38 Bn |
| 10 | Cellectar Biosciences | 6.65 Mn | 6.65 Mn | - | 311.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 311.59 Mn |
| Dec 31, 2025 | -269.13 Mn |
| Sep 30, 2025 | -263.84 Mn |
| Jun 30, 2025 | 264.96 Mn |
| Mar 31, 2025 | 261.68 Mn |
| Dec 31, 2024 | 261.12 Mn |
| Sep 30, 2024 | -244.99 Mn |
| Jun 30, 2024 | -230.32 Mn |
| Mar 31, 2024 | -229.40 Mn |
| Dec 31, 2023 | 182.92 Mn |
| Sep 30, 2023 | -194.88 Mn |
| Jun 30, 2023 | 168.97 Mn |
| Mar 31, 2023 | 168.55 Mn |
| Dec 31, 2022 | 168.14 Mn |
| Sep 30, 2022 | -147.58 Mn |
| Jun 30, 2022 | -140.07 Mn |
| Mar 31, 2022 | 157.56 Mn |
| Dec 31, 2021 | -25.30 Mn |
| Sep 30, 2021 | 182.18 Mn |
| Jun 30, 2021 | 174.51 Mn |